{"id":350331,"date":"2025-08-25T19:19:25","date_gmt":"2025-08-25T19:19:25","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-arvinas\/"},"modified":"2025-08-25T19:19:25","modified_gmt":"2025-08-25T19:19:25","slug":"how-to-buy-arvinas","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/","title":{"rendered":"How to buy Arvinas, Inc. (ARVN) shares &#8211; Investment in Arvinas, Inc. (ARVN) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-350331","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Arvinas, Inc. (ARVN) Shares - Investment in Arvinas, Inc. (ARVN) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Arvinas, Inc. (ARVN) Shares - Investment in Arvinas, Inc. (ARVN) Stock"},"description":"Learn how to buy Arvinas, Inc. (ARVN) shares and make informed investment decisions in this promising biotech stock with FDA catalysts ahead.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to buy Arvinas, Inc. (ARVN) shares and make informed investment decisions in this promising biotech stock with FDA catalysts ahead."},"intro":"Thinking about investing in the future of cancer treatment? Arvinas represents one of the most exciting opportunities in biotech right now. This company is pioneering protein degradation technology that could revolutionize how we treat diseases. We'll break down everything you need to know about investing in ARVN stock\u2014from current performance to the critical FDA decisions that could make or break your investment.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in the future of cancer treatment? Arvinas represents one of the most exciting opportunities in biotech right now. This company is pioneering protein degradation technology that could revolutionize how we treat diseases. We'll break down everything you need to know about investing in ARVN stock\u2014from current performance to the critical FDA decisions that could make or break your investment."},"body_html":"<h2>\ud83d\udcc8 Arvinas Stock: Current Price and Critical Dates<\/h2> <p>As of August 25, 2025, Arvinas, Inc. (ARVN) trades at <strong>$7.39<\/strong> on NASDAQ. Mark your calendar: <strong>October 29, 2025<\/strong> is absolutely critical\u2014that's when Arvinas releases its Q3 earnings. Historically, these reports have moved prices dramatically.<\/p> <h3>How Earnings Reports Move ARVN Stock<\/h3> <p>The last earnings report on August 6, 2025, caused significant volatility. The company reported a 71% revenue decline to $22.4 million due to reduced collaboration income from Pfizer and mixed clinical results for Vepdegestrant. This sent the stock tumbling nearly 15% in the following week.<\/p> <p>Looking back at recent history:<\/p> <ul> <li><strong>February 2025<\/strong>: Q4 earnings caused a 12% drop on disappointing trial updates<\/li> <li><strong>November 2024<\/strong>: Partnership news with Genentech sparked a 22% rally<\/li> <li><strong>August 2024<\/strong>: Q2 results showed progress but missed revenue estimates, leading to an 8% decline<\/li> <li><strong>May 2024<\/strong>: Positive Phase 2 data created a 30% surge over two weeks<\/li> <\/ul> <p>The pattern is clear: ARVN reacts strongly to clinical trial results and partnership announcements. The upcoming October earnings could be particularly volatile given the recent revenue challenges.<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udcca 6-Month Price Journey (February-August 2025)<\/h2> <p>Arvinas shares have experienced a rollercoaster ride over the past six months:<\/p> <p><strong>February 2025<\/strong>: $9.80 (post-Q4 earnings disappointment)<br\/> <strong>March 2025<\/strong>: $11.20 (recovery on partnership optimism)<br\/> <strong>April 2025<\/strong>: $8.90 (volatility from sector-wide biotech selloff)<br\/> <strong>May 2025<\/strong>: $10.50 (positive analyst upgrades)<br\/> <strong>June 2025<\/strong>: $7.20 (sharp drop on revenue concerns)<br\/> <strong>July 2025<\/strong>: $6.80 (touched 52-week low)<br\/> <strong>August 2025<\/strong>: $7.39 (current stabilization)<\/p> <p>This represents a <strong>24.6% decline<\/strong> over the six-month period, primarily driven by:<\/p> <ul> <li>Clinical trial uncertainties<\/li> <li>Revenue shortfalls from Pfizer collaborations<\/li> <li>Broader biotech sector weakness<\/li> <\/ul> <p>However, the stock has shown resilience around the $7 support level, suggesting potential stabilization.<\/p> <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <p>Based on current analyst consensus and clinical development timelines:<\/p> <ul> <li><strong>2025 Year-End<\/strong>: $14-18 range (assuming stabilization and modest recovery) \u2192 <strong>BUY for long-term<\/strong><\/li> <li><strong>2026 Target<\/strong>: $20-25 (FDA decision on Vepdegestrant expected June 2026)<\/li> <li><strong>2028 Projection<\/strong>: $35-45 (potential commercialization and expanded partnerships)<\/li> <li><strong>2030 Vision<\/strong>: $60-80+ (if protein degradation platform proves successful across multiple indications)<\/li> <\/ul> <p>The average analyst price target sits at <strong>$20.21<\/strong> according to recent data from <a href=\"https:\/\/stockanalysis.com\/stocks\/arvn\/forecast\/\">StockAnalysis.com<\/a>, representing a 176% upside potential from current levels.<\/p> <h3>Why the Bullish Long-Term Outlook?<\/h3> <ol> <li><strong>FDA Catalyst<\/strong>: June 5, 2026 PDUFA date for Vepdegestrant<\/li> <li><strong>Platform Potential<\/strong>: PROTAC technology could address \"undruggable\" targets<\/li> <li><strong>Strong Partnerships<\/strong>: Pfizer collaboration reduces development risk<\/li> <li><strong>Cash Runway<\/strong>: Sufficient funds until late 2028 per latest reports<\/li> <\/ol> <h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2> <h3>Risks to Consider<\/h3> <ul> <li><strong>Clinical Trial Failures<\/strong>: 90% of drug candidates fail in late-stage trials<\/li> <li><strong>Regulatory Delays<\/strong>: FDA decisions can be postponed or require additional data<\/li> <li><strong>Revenue Dependency<\/strong>: Heavy reliance on partnership payments until commercialization<\/li> <li><strong>High Volatility<\/strong>: Beta of 1.58 means 58% more volatile than market<\/li> <li><strong>Binary Events<\/strong>: Stock price heavily dependent on few key catalysts<\/li> <\/ul> <h3>Green Lights for 2025-2026<\/h3> <ul> <li><strong>FDA Acceptance<\/strong>: Vepdegestrant NDA accepted with June 2026 decision date<\/li> <li><strong>Phase 3 Success<\/strong>: 43% risk reduction in disease progression shown in trials<\/li> <li><strong>Institutional Support<\/strong>: XTX Topco increased stake by 194% in Q1 2025<\/li> <li><strong>Analyst Confidence<\/strong>: 12 buy ratings, 9 holds, zero sell recommendations<\/li> <li><strong>Technology Validation<\/strong>: First PROTAC drug approaching FDA review<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Start Small<\/strong>: Allocate no more than 2-3% of your portfolio to high-risk biotech stocks<\/li> <li><strong>Dollar-Cost Average<\/strong>: Buy in increments rather than all at once to reduce timing risk<\/li> <li><strong>Set Price Alerts<\/strong>: Monitor around key dates like October 29 earnings<\/li> <li><strong>Have an Exit Strategy<\/strong>: Know your stop-loss levels before entering the trade<\/li> <\/ol> <p>Humorous take: \"Trading ARVN is like watching a medical drama\u2014plenty of suspense, occasional breakthroughs, and you'll need strong nerves for the season finale (FDA decision)!\"<\/p> <h2>\u2705 How to Buy Arvinas, Inc. (ARVN) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose a trading platform<\/td><td>Ensure it offers NASDAQ listings and fractional shares<\/td><\/tr> <tr><td>2<\/td><td>Complete account verification<\/td><td>Typically requires ID and proof of address<\/td><\/tr> <tr><td>3<\/td><td>Deposit funds<\/td><td>Start with an amount you're comfortable risking<\/td><\/tr> <tr><td>4<\/td><td>Search \"ARVN\"<\/td><td>Use the ticker symbol, not just the company name<\/td><\/tr> <tr><td>5<\/td><td>Select order type<\/td><td>Use limit orders to control entry price<\/td><\/tr> <tr><td>6<\/td><td>Review and confirm<\/td><td>Check commission fees and total cost<\/td><\/tr> <tr><td>7<\/td><td>Monitor your position<\/td><td>Set alerts for news and price movements<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2> <p>For those looking to dip their toes into biotech investing, Pocket Option offers several advantages:<\/p> <ul> <li><strong>Minimum deposit of just $5<\/strong> \u2014 perfect for testing strategies with small amounts<\/li> <li><strong>Quick verification<\/strong> \u2014 typically under 1 minute with any government ID<\/li> <li><strong>Fractional shares available<\/strong> \u2014 buy portions of expensive stocks<\/li> <li><strong>100+ withdrawal methods<\/strong> \u2014 including crypto, e-wallets, and bank transfers<\/li> <\/ul> <p>The platform's user-friendly interface makes it ideal for beginners who want to explore biotech stocks like ARVN without committing large amounts of capital initially.<\/p> <h2>\ud83c\udf0d Arvinas in 2025: Protein Degradation Pioneer<\/h2> <p>Arvinas stands at the forefront of targeted protein degradation technology. The company's PROTAC platform represents a potential paradigm shift in treating diseases by harnessing the body's natural protein disposal system instead of traditional inhibition approaches.<\/p> <ul> <li><strong>Current Focus<\/strong>: Advancing Vepdegestrant for breast cancer with FDA decision expected June 2026<\/li> <li><strong>Pipeline Strength<\/strong>: Multiple candidates in Phase 3 trials for prostate cancer and other indications<\/li> <li><strong>Partnership Power<\/strong>: Collaborations with Pfizer, Genentech, and Bayer provide financial stability<\/li> <\/ul> <p><strong>2025 Interesting Fact<\/strong>: Arvinas scientists discovered that their protein degraders can be designed to be \"event-driven\" rather than \"occupancy-driven,\" meaning they work only when needed and then naturally disengage\u2014a breakthrough that could reduce side effects significantly.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Arvinas Stock: Current Price and Critical Dates<\/h2>\n<p>As of August 25, 2025, Arvinas, Inc. (ARVN) trades at <strong>$7.39<\/strong> on NASDAQ. Mark your calendar: <strong>October 29, 2025<\/strong> is absolutely critical\u2014that&#8217;s when Arvinas releases its Q3 earnings. Historically, these reports have moved prices dramatically.<\/p>\n<h3>How Earnings Reports Move ARVN Stock<\/h3>\n<p>The last earnings report on August 6, 2025, caused significant volatility. The company reported a 71% revenue decline to $22.4 million due to reduced collaboration income from Pfizer and mixed clinical results for Vepdegestrant. This sent the stock tumbling nearly 15% in the following week.<\/p>\n<p>Looking back at recent history:<\/p>\n<ul>\n<li><strong>February 2025<\/strong>: Q4 earnings caused a 12% drop on disappointing trial updates<\/li>\n<li><strong>November 2024<\/strong>: Partnership news with Genentech sparked a 22% rally<\/li>\n<li><strong>August 2024<\/strong>: Q2 results showed progress but missed revenue estimates, leading to an 8% decline<\/li>\n<li><strong>May 2024<\/strong>: Positive Phase 2 data created a 30% surge over two weeks<\/li>\n<\/ul>\n<p>The pattern is clear: ARVN reacts strongly to clinical trial results and partnership announcements. The upcoming October earnings could be particularly volatile given the recent revenue challenges.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6-Month Price Journey (February-August 2025)<\/h2>\n<p>Arvinas shares have experienced a rollercoaster ride over the past six months:<\/p>\n<p><strong>February 2025<\/strong>: $9.80 (post-Q4 earnings disappointment)<br \/> <strong>March 2025<\/strong>: $11.20 (recovery on partnership optimism)<br \/> <strong>April 2025<\/strong>: $8.90 (volatility from sector-wide biotech selloff)<br \/> <strong>May 2025<\/strong>: $10.50 (positive analyst upgrades)<br \/> <strong>June 2025<\/strong>: $7.20 (sharp drop on revenue concerns)<br \/> <strong>July 2025<\/strong>: $6.80 (touched 52-week low)<br \/> <strong>August 2025<\/strong>: $7.39 (current stabilization)<\/p>\n<p>This represents a <strong>24.6% decline<\/strong> over the six-month period, primarily driven by:<\/p>\n<ul>\n<li>Clinical trial uncertainties<\/li>\n<li>Revenue shortfalls from Pfizer collaborations<\/li>\n<li>Broader biotech sector weakness<\/li>\n<\/ul>\n<p>However, the stock has shown resilience around the $7 support level, suggesting potential stabilization.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<p>Based on current analyst consensus and clinical development timelines:<\/p>\n<ul>\n<li><strong>2025 Year-End<\/strong>: $14-18 range (assuming stabilization and modest recovery) \u2192 <strong>BUY for long-term<\/strong><\/li>\n<li><strong>2026 Target<\/strong>: $20-25 (FDA decision on Vepdegestrant expected June 2026)<\/li>\n<li><strong>2028 Projection<\/strong>: $35-45 (potential commercialization and expanded partnerships)<\/li>\n<li><strong>2030 Vision<\/strong>: $60-80+ (if protein degradation platform proves successful across multiple indications)<\/li>\n<\/ul>\n<p>The average analyst price target sits at <strong>$20.21<\/strong> according to recent data from <a href=\"https:\/\/stockanalysis.com\/stocks\/arvn\/forecast\/\">StockAnalysis.com<\/a>, representing a 176% upside potential from current levels.<\/p>\n<h3>Why the Bullish Long-Term Outlook?<\/h3>\n<ol>\n<li><strong>FDA Catalyst<\/strong>: June 5, 2026 PDUFA date for Vepdegestrant<\/li>\n<li><strong>Platform Potential<\/strong>: PROTAC technology could address &#8220;undruggable&#8221; targets<\/li>\n<li><strong>Strong Partnerships<\/strong>: Pfizer collaboration reduces development risk<\/li>\n<li><strong>Cash Runway<\/strong>: Sufficient funds until late 2028 per latest reports<\/li>\n<\/ol>\n<h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2>\n<h3>Risks to Consider<\/h3>\n<ul>\n<li><strong>Clinical Trial Failures<\/strong>: 90% of drug candidates fail in late-stage trials<\/li>\n<li><strong>Regulatory Delays<\/strong>: FDA decisions can be postponed or require additional data<\/li>\n<li><strong>Revenue Dependency<\/strong>: Heavy reliance on partnership payments until commercialization<\/li>\n<li><strong>High Volatility<\/strong>: Beta of 1.58 means 58% more volatile than market<\/li>\n<li><strong>Binary Events<\/strong>: Stock price heavily dependent on few key catalysts<\/li>\n<\/ul>\n<h3>Green Lights for 2025-2026<\/h3>\n<ul>\n<li><strong>FDA Acceptance<\/strong>: Vepdegestrant NDA accepted with June 2026 decision date<\/li>\n<li><strong>Phase 3 Success<\/strong>: 43% risk reduction in disease progression shown in trials<\/li>\n<li><strong>Institutional Support<\/strong>: XTX Topco increased stake by 194% in Q1 2025<\/li>\n<li><strong>Analyst Confidence<\/strong>: 12 buy ratings, 9 holds, zero sell recommendations<\/li>\n<li><strong>Technology Validation<\/strong>: First PROTAC drug approaching FDA review<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Start Small<\/strong>: Allocate no more than 2-3% of your portfolio to high-risk biotech stocks<\/li>\n<li><strong>Dollar-Cost Average<\/strong>: Buy in increments rather than all at once to reduce timing risk<\/li>\n<li><strong>Set Price Alerts<\/strong>: Monitor around key dates like October 29 earnings<\/li>\n<li><strong>Have an Exit Strategy<\/strong>: Know your stop-loss levels before entering the trade<\/li>\n<\/ol>\n<p>Humorous take: &#8220;Trading ARVN is like watching a medical drama\u2014plenty of suspense, occasional breakthroughs, and you&#8217;ll need strong nerves for the season finale (FDA decision)!&#8221;<\/p>\n<h2>\u2705 How to Buy Arvinas, Inc. (ARVN) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a trading platform<\/td>\n<td>Ensure it offers NASDAQ listings and fractional shares<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete account verification<\/td>\n<td>Typically requires ID and proof of address<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Deposit funds<\/td>\n<td>Start with an amount you&#8217;re comfortable risking<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Search &#8220;ARVN&#8221;<\/td>\n<td>Use the ticker symbol, not just the company name<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Select order type<\/td>\n<td>Use limit orders to control entry price<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Review and confirm<\/td>\n<td>Check commission fees and total cost<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Monitor your position<\/td>\n<td>Set alerts for news and price movements<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2>\n<p>For those looking to dip their toes into biotech investing, Pocket Option offers several advantages:<\/p>\n<ul>\n<li><strong>Minimum deposit of just $5<\/strong> \u2014 perfect for testing strategies with small amounts<\/li>\n<li><strong>Quick verification<\/strong> \u2014 typically under 1 minute with any government ID<\/li>\n<li><strong>Fractional shares available<\/strong> \u2014 buy portions of expensive stocks<\/li>\n<li><strong>100+ withdrawal methods<\/strong> \u2014 including crypto, e-wallets, and bank transfers<\/li>\n<\/ul>\n<p>The platform&#8217;s user-friendly interface makes it ideal for beginners who want to explore biotech stocks like ARVN without committing large amounts of capital initially.<\/p>\n<h2>\ud83c\udf0d Arvinas in 2025: Protein Degradation Pioneer<\/h2>\n<p>Arvinas stands at the forefront of targeted protein degradation technology. The company&#8217;s PROTAC platform represents a potential paradigm shift in treating diseases by harnessing the body&#8217;s natural protein disposal system instead of traditional inhibition approaches.<\/p>\n<ul>\n<li><strong>Current Focus<\/strong>: Advancing Vepdegestrant for breast cancer with FDA decision expected June 2026<\/li>\n<li><strong>Pipeline Strength<\/strong>: Multiple candidates in Phase 3 trials for prostate cancer and other indications<\/li>\n<li><strong>Partnership Power<\/strong>: Collaborations with Pfizer, Genentech, and Bayer provide financial stability<\/li>\n<\/ul>\n<p><strong>2025 Interesting Fact<\/strong>: Arvinas scientists discovered that their protein degraders can be designed to be &#8220;event-driven&#8221; rather than &#8220;occupancy-driven,&#8221; meaning they work only when needed and then naturally disengage\u2014a breakthrough that could reduce side effects significantly.<\/p>\n"},"faq":[{"question":"What is the biggest risk with investing in ARVN stock?","answer":"The primary risk is clinical trial failure or FDA rejection of Vepdegestrant in June 2026, which could cause significant price declines."},{"question":"How long should I plan to hold ARVN shares?","answer":"Given the June 2026 FDA catalyst, a minimum 12-18 month horizon is reasonable to see through the key regulatory decision."},{"question":"Does Arvinas pay dividends?","answer":"No, as a clinical-stage biotech company, Arvinas reinvests all capital into research and development rather than paying dividends."},{"question":"What percentage of my portfolio should be in biotech stocks like ARVN?","answer":"Most financial advisors recommend limiting high-risk biotech exposure to 5-10% of your total portfolio for diversification."},{"question":"How often does Arvinas release financial results?","answer":"The company reports quarterly earnings, typically in February, May, August, and November each year."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"What is the biggest risk with investing in ARVN stock?","answer":"The primary risk is clinical trial failure or FDA rejection of Vepdegestrant in June 2026, which could cause significant price declines."},{"question":"How long should I plan to hold ARVN shares?","answer":"Given the June 2026 FDA catalyst, a minimum 12-18 month horizon is reasonable to see through the key regulatory decision."},{"question":"Does Arvinas pay dividends?","answer":"No, as a clinical-stage biotech company, Arvinas reinvests all capital into research and development rather than paying dividends."},{"question":"What percentage of my portfolio should be in biotech stocks like ARVN?","answer":"Most financial advisors recommend limiting high-risk biotech exposure to 5-10% of your total portfolio for diversification."},{"question":"How often does Arvinas release financial results?","answer":"The company reports quarterly earnings, typically in February, May, August, and November each year."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy Arvinas, Inc. (ARVN) shares - Investment in Arvinas, Inc. (ARVN) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy Arvinas, Inc. (ARVN) shares - Investment in Arvinas, Inc. (ARVN) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T19:19:25+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy Arvinas, Inc. (ARVN) shares &#8211; Investment in Arvinas, Inc. (ARVN) stock\",\"datePublished\":\"2025-08-25T19:19:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/\"},\"wordCount\":15,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/\",\"name\":\"How to buy Arvinas, Inc. (ARVN) shares - Investment in Arvinas, Inc. (ARVN) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"datePublished\":\"2025-08-25T19:19:25+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy Arvinas, Inc. (ARVN) shares &#8211; Investment in Arvinas, Inc. (ARVN) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy Arvinas, Inc. (ARVN) shares - Investment in Arvinas, Inc. (ARVN) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/","og_locale":"en_US","og_type":"article","og_title":"How to buy Arvinas, Inc. (ARVN) shares - Investment in Arvinas, Inc. (ARVN) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T19:19:25+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy Arvinas, Inc. (ARVN) shares &#8211; Investment in Arvinas, Inc. (ARVN) stock","datePublished":"2025-08-25T19:19:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/"},"wordCount":15,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/","name":"How to buy Arvinas, Inc. (ARVN) shares - Investment in Arvinas, Inc. (ARVN) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","datePublished":"2025-08-25T19:19:25+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-arvinas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy Arvinas, Inc. (ARVN) shares &#8211; Investment in Arvinas, Inc. (ARVN) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":350456,"slug":"how-to-buy-arvinas","post_title":"Comment acheter des actions Arvinas, Inc. (ARVN) - Investir dans les actions Arvinas, Inc. (ARVN)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-arvinas\/"},"it_IT":{"locale":"it_IT","id":350458,"slug":"how-to-buy-arvinas","post_title":"Come acquistare azioni Arvinas, Inc. (ARVN) - Investire in azioni Arvinas, Inc. (ARVN)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-arvinas\/"},"pl_PL":{"locale":"pl_PL","id":350460,"slug":"how-to-buy-arvinas","post_title":"Jak kupi\u0107 akcje Arvinas, Inc. (ARVN) - Inwestycja w akcje Arvinas, Inc. (ARVN)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-arvinas\/"},"es_ES":{"locale":"es_ES","id":350454,"slug":"how-to-buy-arvinas","post_title":"C\u00f3mo comprar acciones de Arvinas, Inc. (ARVN) - Inversi\u00f3n en acciones de Arvinas, Inc. (ARVN)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-arvinas\/"},"th_TH":{"locale":"th_TH","id":350461,"slug":"how-to-buy-arvinas","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 Arvinas, Inc. (ARVN) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 Arvinas, Inc. (ARVN)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-arvinas\/"},"tr_TR":{"locale":"tr_TR","id":350455,"slug":"how-to-buy-arvinas","post_title":"Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arvinas, Inc. (ARVN) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/"},"vt_VT":{"locale":"vt_VT","id":350457,"slug":"how-to-buy-arvinas","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Arvinas, Inc. (ARVN) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Arvinas, Inc. (ARVN)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-arvinas\/"},"pt_AA":{"locale":"pt_AA","id":350459,"slug":"how-to-buy-arvinas","post_title":"Como comprar a\u00e7\u00f5es da Arvinas, Inc. (ARVN) - Investimento em a\u00e7\u00f5es da Arvinas, Inc. (ARVN)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-arvinas\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/350331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=350331"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/350331\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334081"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=350331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=350331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=350331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}